PAREA
@pareascience.bsky.social
Advocating in Europe for modern, rational, safe, and ethically responsible integration of psychedelic-assisted therapies into mainstream health services.
US agencies are moving fast on psychedelic therapies: clinical guidance, regulatory readiness, cross-agency work, following April's EO on mental health and ARPA-H's $100M moonshot. Europe shouldn't wait. PAREA wants mental health reflected across the EU Biotech Act.
tinyurl.com/parea-news
tinyurl.com/parea-news
July 15, 2026 at 1:30 PM
US agencies are moving fast on psychedelic therapies: clinical guidance, regulatory readiness, cross-agency work, following April's EO on mental health and ARPA-H's $100M moonshot. Europe shouldn't wait. PAREA wants mental health reflected across the EU Biotech Act.
tinyurl.com/parea-news
tinyurl.com/parea-news
🚨 The June EU Insights newsletter is out 🚨
Highlights:
• PAREA's Biotech Act recommendations to the European Commission.
• Updates from the European Academy of Neurology Congress.
• PsyPal trial expansion across Europe.
• Francisca Silva speaking at PSY-NET during FENS.
Read more: lnkd.in/dc3RXaAd
Highlights:
• PAREA's Biotech Act recommendations to the European Commission.
• Updates from the European Academy of Neurology Congress.
• PsyPal trial expansion across Europe.
• Francisca Silva speaking at PSY-NET during FENS.
Read more: lnkd.in/dc3RXaAd
June 30, 2026 at 10:01 AM
🚨 The June EU Insights newsletter is out 🚨
Highlights:
• PAREA's Biotech Act recommendations to the European Commission.
• Updates from the European Academy of Neurology Congress.
• PsyPal trial expansion across Europe.
• Francisca Silva speaking at PSY-NET during FENS.
Read more: lnkd.in/dc3RXaAd
Highlights:
• PAREA's Biotech Act recommendations to the European Commission.
• Updates from the European Academy of Neurology Congress.
• PsyPal trial expansion across Europe.
• Francisca Silva speaking at PSY-NET during FENS.
Read more: lnkd.in/dc3RXaAd
We're pleased to welcome Psychedelic Lived Experiences as PAREA's newest Community Supporter! They elevate patient voices in psychedelic care through advocacy, education, and community because lived experience is genuine expertise.
Learn more: parea.eu/parea-news/p...
Learn more: parea.eu/parea-news/p...
June 16, 2026 at 11:56 AM
We're pleased to welcome Psychedelic Lived Experiences as PAREA's newest Community Supporter! They elevate patient voices in psychedelic care through advocacy, education, and community because lived experience is genuine expertise.
Learn more: parea.eu/parea-news/p...
Learn more: parea.eu/parea-news/p...
We submitted our response to the European Commission’s consultation on the EU4Health 2027 Work Programme. We call for stronger health systems to address NCDs, with mental health as a core priority, alongside support for workforce development, implementation, and access to care. lnkd.in/dSQJauZh
June 12, 2026 at 12:12 PM
We submitted our response to the European Commission’s consultation on the EU4Health 2027 Work Programme. We call for stronger health systems to address NCDs, with mental health as a core priority, alongside support for workforce development, implementation, and access to care. lnkd.in/dSQJauZh
PAREA has submitted recommendations to the EU Commission’s upcoming Biotech Act consultation, calling for mental health innovation to be included in Europe’s biotech strategy. Mental health innovation is both a public health priority and a competitiveness opportunity for Europe. lnkd.in/ee6cEgb8
May 26, 2026 at 10:47 AM
PAREA has submitted recommendations to the EU Commission’s upcoming Biotech Act consultation, calling for mental health innovation to be included in Europe’s biotech strategy. Mental health innovation is both a public health priority and a competitiveness opportunity for Europe. lnkd.in/ee6cEgb8
France expands access to ketamine for patients in suicidal crisis. A 3 year programme allows IV racemic ketamine for adults with acute suicidal ideation, prescribed by psychiatrists and delivered in hospitals. Based on strong evidence and lower cost compared to esketamine. parea.eu/parea-news/f...
April 21, 2026 at 9:27 AM
France expands access to ketamine for patients in suicidal crisis. A 3 year programme allows IV racemic ketamine for adults with acute suicidal ideation, prescribed by psychiatrists and delivered in hospitals. Based on strong evidence and lower cost compared to esketamine. parea.eu/parea-news/f...
At the EPA Congress in Prague, PAREA engaged with clinicians and professionals on the role of psychedelic therapies in mental health care. Strong turnout for David Nutt’s sessions reflects growing interest in moving these approaches into clinical practice. More here: tinyurl.com/parea-at-the...
March 31, 2026 at 1:26 PM
At the EPA Congress in Prague, PAREA engaged with clinicians and professionals on the role of psychedelic therapies in mental health care. Strong turnout for David Nutt’s sessions reflects growing interest in moving these approaches into clinical practice. More here: tinyurl.com/parea-at-the...
Today marks the launch of a new PsyPal guidance paper on how to standardise and implement psychedelic therapies in Europe. PAREA contributed to this work alongside partners in the PsyPal consortium. It outlines practical steps for moving toward real-world integration. tinyurl.com/psypal-guida...
March 30, 2026 at 2:27 PM
Today marks the launch of a new PsyPal guidance paper on how to standardise and implement psychedelic therapies in Europe. PAREA contributed to this work alongside partners in the PsyPal consortium. It outlines practical steps for moving toward real-world integration. tinyurl.com/psypal-guida...
PAREA is co-organising a webinar on the EU-funded PsyPal project, exploring psilocybin-assisted therapy for psychological distress in palliative care, incl. neurological conditions.
13 April, 14:00 to 15:30 CEST, with the EU Health Policy Platform. Register here: tinyurl.com/psypal-webinar
13 April, 14:00 to 15:30 CEST, with the EU Health Policy Platform. Register here: tinyurl.com/psypal-webinar
March 25, 2026 at 8:12 AM
PAREA is co-organising a webinar on the EU-funded PsyPal project, exploring psilocybin-assisted therapy for psychological distress in palliative care, incl. neurological conditions.
13 April, 14:00 to 15:30 CEST, with the EU Health Policy Platform. Register here: tinyurl.com/psypal-webinar
13 April, 14:00 to 15:30 CEST, with the EU Health Policy Platform. Register here: tinyurl.com/psypal-webinar
PAREA will be at the European Psychiatric Association Congress in Prague, 28–31 March. We will be hosting a stand to engage with the psychiatric community on the current status and potential of psychedelic therapies. Find us at our stand in the exhibition hall! More info: parea.eu/events/parea...
March 23, 2026 at 1:39 PM
PAREA will be at the European Psychiatric Association Congress in Prague, 28–31 March. We will be hosting a stand to engage with the psychiatric community on the current status and potential of psychedelic therapies. Find us at our stand in the exhibition hall! More info: parea.eu/events/parea...
A psychedelic compound, bretisilocin, has entered the EMA PRIME scheme for major depressive disorder. PRIME supports high need medicines through early regulatory engagement, marking a meaningful step for Europe’s role in mental health innovation. Read more: tinyurl.com/news-release...
March 20, 2026 at 11:57 AM
A psychedelic compound, bretisilocin, has entered the EMA PRIME scheme for major depressive disorder. PRIME supports high need medicines through early regulatory engagement, marking a meaningful step for Europe’s role in mental health innovation. Read more: tinyurl.com/news-release...
Webinar on legal pathways for psychedelic therapies in Europe, March 20 at 18:00 CET. PAREA joins UPRA and Ukraine’s Public Health Centre, with Marion Haberkamp, João Taborda da Gama, and Pavel Pachta. Register here: parea.eu/events/webin...
March 18, 2026 at 2:45 PM
Webinar on legal pathways for psychedelic therapies in Europe, March 20 at 18:00 CET. PAREA joins UPRA and Ukraine’s Public Health Centre, with Marion Haberkamp, João Taborda da Gama, and Pavel Pachta. Register here: parea.eu/events/webin...
Join our European Parliament event on psychedelic research and access for war related mental health needs in Ukraine, including PTSD among veterans.
6 May 2026, 14:30 to 16:30, Brussels and online
Register here: parea.eu/events/psych...
6 May 2026, 14:30 to 16:30, Brussels and online
Register here: parea.eu/events/psych...
March 17, 2026 at 2:50 PM
Join our European Parliament event on psychedelic research and access for war related mental health needs in Ukraine, including PTSD among veterans.
6 May 2026, 14:30 to 16:30, Brussels and online
Register here: parea.eu/events/psych...
6 May 2026, 14:30 to 16:30, Brussels and online
Register here: parea.eu/events/psych...
We welcome HYSTELICA as PAREA’s newest Community Supporter! The nonprofit advances psychedelic science for women through research, advocacy, and education. They focus on how psychedelics interact with female biology and closing gaps in women’s health research. More here: tinyurl.com/hystelica
March 9, 2026 at 2:54 PM
We welcome HYSTELICA as PAREA’s newest Community Supporter! The nonprofit advances psychedelic science for women through research, advocacy, and education. They focus on how psychedelics interact with female biology and closing gaps in women’s health research. More here: tinyurl.com/hystelica
Compass Pathways released topline data from its second Phase 3 trial of COMP360 psilocybin in treatment resistant depression. In COMP006 (n=581), two 25 mg doses showed a -3.8 MADRS difference vs 1 mg at Week 6. Prior Phase 3 data showed -3.6 vs placebo. More: tinyurl.com/readout-for-...
February 18, 2026 at 12:34 PM
Compass Pathways released topline data from its second Phase 3 trial of COMP360 psilocybin in treatment resistant depression. In COMP006 (n=581), two 25 mg doses showed a -3.8 MADRS difference vs 1 mg at Week 6. Prior Phase 3 data showed -3.6 vs placebo. More: tinyurl.com/readout-for-...
Spain’s Parliament hosted its first conference on psychedelic assisted psychotherapies on February 13. Clinicians, researchers, and regulators focused on evidence, responsible training, and equity in access. The debate has now formally entered the legislative arena. Learn more: tinyurl.com/spain-pap
February 17, 2026 at 11:41 AM
Spain’s Parliament hosted its first conference on psychedelic assisted psychotherapies on February 13. Clinicians, researchers, and regulators focused on evidence, responsible training, and equity in access. The debate has now formally entered the legislative arena. Learn more: tinyurl.com/spain-pap
PAREA submitted feedback on the European Commission’s ERA Act consultation, urging mental health as a strategic R&I priority and better coordinated funding that protects scientific freedom and speeds translation into practice. Learn more: parea.eu/parea-news/p...
January 16, 2026 at 9:07 AM
PAREA submitted feedback on the European Commission’s ERA Act consultation, urging mental health as a strategic R&I priority and better coordinated funding that protects scientific freedom and speeds translation into practice. Learn more: parea.eu/parea-news/p...
EU institutions have agreed on the 1st major revision of pharmaceutical legislation in 20 years, reshaping incentives, access rules, and introducing regulatory sandboxes. PAREA will keep pushing for mental health to be recognised as the package moves forward. Learn more: tinyurl.com/pharma-legis...
December 16, 2025 at 1:31 PM
EU institutions have agreed on the 1st major revision of pharmaceutical legislation in 20 years, reshaping incentives, access rules, and introducing regulatory sandboxes. PAREA will keep pushing for mental health to be recognised as the package moves forward. Learn more: tinyurl.com/pharma-legis...
New article maps key regulatory and clinical hurdles for bringing psychedelic therapies into EU healthcare. It underlines HTA as the decisive barrier and notes psychotherapy + pharmacotherapy as the gold standard, raising questions for assessing added value. More details: tinyurl.com/therapy-path...
What Europe’s health systems will require to implement psychedelic therapies — PAREA
A new article published in European Neuropsychopharmacology provides a critical assessment of what psychedelic therapi es would need in order to be integrated into European healthcare systems. ...
tinyurl.com
December 9, 2025 at 1:56 PM
New article maps key regulatory and clinical hurdles for bringing psychedelic therapies into EU healthcare. It underlines HTA as the decisive barrier and notes psychotherapy + pharmacotherapy as the gold standard, raising questions for assessing added value. More details: tinyurl.com/therapy-path...
PAREA will join the PSYCH Symposium in London on Dec 4. Our Project Officer, Francisca Silva, will speak on integrating psychedelic medicines into healthcare alongside the MIND Foundation, Dr Liliana Galindo and Jeff Smith MP. Learn more about the conference here: www.psychsymposium.com/agenda
November 27, 2025 at 10:50 AM
PAREA will join the PSYCH Symposium in London on Dec 4. Our Project Officer, Francisca Silva, will speak on integrating psychedelic medicines into healthcare alongside the MIND Foundation, Dr Liliana Galindo and Jeff Smith MP. Learn more about the conference here: www.psychsymposium.com/agenda
The US just launched EVIDENT, a 100M mental health moonshot days after PAREA called for a mission driven mental health moonshot in Europe. Neuroplastogens included. Clear signal that mental health innovation is going strategic. Europe has a window to lead. Learn more: parea.eu/parea-news/1...
November 24, 2025 at 5:48 PM
The US just launched EVIDENT, a 100M mental health moonshot days after PAREA called for a mission driven mental health moonshot in Europe. Neuroplastogens included. Clear signal that mental health innovation is going strategic. Europe has a window to lead. Learn more: parea.eu/parea-news/1...
Mental health innovation is rising in Europe and PAREA is at the centre. From calling for a European Mental Health Moonshot to EU-backed psychedelic trials, new members, major policy input, and the PsyPal trial now recruiting.
Read the full newsletter: view.flodesk.com/emails/691d8...
Read the full newsletter: view.flodesk.com/emails/691d8...
November 19, 2025 at 2:29 PM
Mental health innovation is rising in Europe and PAREA is at the centre. From calling for a European Mental Health Moonshot to EU-backed psychedelic trials, new members, major policy input, and the PsyPal trial now recruiting.
Read the full newsletter: view.flodesk.com/emails/691d8...
Read the full newsletter: view.flodesk.com/emails/691d8...
PAREA welcomes the Women’s Brain Foundation as a new full member. Together, we’re pushing for sex and gender differences to be systematically recognised in mental health and psychedelic research, policy, and innovation across Europe.
Learn more: view.flodesk.com/emails/6911d...
Learn more: view.flodesk.com/emails/6911d...
November 12, 2025 at 10:56 AM
PAREA welcomes the Women’s Brain Foundation as a new full member. Together, we’re pushing for sex and gender differences to be systematically recognised in mental health and psychedelic research, policy, and innovation across Europe.
Learn more: view.flodesk.com/emails/6911d...
Learn more: view.flodesk.com/emails/6911d...
PAREA is partnering with the HoloMind: Psychedelic Therapy and Integration Conference 2025, Nov 15–16 in Warsaw and online. Experts will explore how psychedelics can help treat depression, PTSD, and addiction, and how Europe can connect evidence, ethics, and practice.
holomind.org/en/2nd-editi...
holomind.org/en/2nd-editi...
November 7, 2025 at 9:25 AM
PAREA is partnering with the HoloMind: Psychedelic Therapy and Integration Conference 2025, Nov 15–16 in Warsaw and online. Experts will explore how psychedelics can help treat depression, PTSD, and addiction, and how Europe can connect evidence, ethics, and practice.
holomind.org/en/2nd-editi...
holomind.org/en/2nd-editi...
We’re proud to support the first-ever Psychedelic Lived Experiences Summit! Nov 21-23| Free & Virtual
This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers.
🎟️ Register: psychedeliclivedexperiences.com/summit
This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers.
🎟️ Register: psychedeliclivedexperiences.com/summit
October 24, 2025 at 1:20 PM
We’re proud to support the first-ever Psychedelic Lived Experiences Summit! Nov 21-23| Free & Virtual
This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers.
🎟️ Register: psychedeliclivedexperiences.com/summit
This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers.
🎟️ Register: psychedeliclivedexperiences.com/summit